IPSC0054, GBA L444P (CBIGi041-A) correction
The cell line is not validated yet.
CBIGi041-A-1
General
Cell Line |
|
| hPSCreg name | CBIGi041-A-1 |
| Cite as: | CBIGi041-A-1 |
| Alternative name(s) |
IPSC0054, GBA L444P (CBIGi041-A) correction
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
CBIGi041-A (IPSC0053, GBA L444P (CBIGi041-A)) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease CBIGi042-A-1 (GBA E326K (CBIGi042-A) correction, IPSC0056) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease CBIGi042-A (IPSC0055, GBA E326K (CBIGi042-A)) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease CBIGi045-A (GBA L444P(CBIGi045-A), IPSC0077) Donor's gene variants: GBA, GBA Donor diseases: Parkinson Disease LCSBi017-A (M1 Cl6b, #89721) Donor's gene variants: GBA1, GBA1, GBA1, GBA1 Donor diseases: Parkinson Disease CBIGi002-A (2890 (GBA W378G, heterozygous), 2890, IPSC0001) Donor's gene variants: GBA, GBA, GBA Donor diseases: Parkinson Disease CBIGi002-A-1 (GBA W378G-correction/2890, 2890-iso, IPSC0002) Donor's gene variants: GBA, GBA, GBA Donor diseases: Parkinson Disease CBIGi001-A-40 (IPSC0112, GBA-KO/AIW002-02) WIBRe001-A-83 (WIBR3_GBA1_IVS2_G2E) WIBRe001-A-84 (WIBR3_GBA1_IVS2_E10B) |
| Last update | 30th July 2025 |
| Notes | Isogenic control for CBIGi041-A. |
| User feedback | |
Provider |
|
| Generator | Clinical Biospecimen Imaging and Genetic (C-BIG) Repository (CBIG) |
| Distributors | |
| Derivation country | Canada |
External Databases |
|
| BioSamples | SAMEA117982038 |
General Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclone of | |
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA117982037 |
Ethics
Also have a look at the ethics information for the parental line
CBIGi041-A
.
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
CBIGi041-A.
|
|
| Passage number reprogrammed | P14 |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Episomal |
| Genes | |
| Is reprogramming vector detectable? |
Unknown |
| Methods used |
Immunostaining
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Passage method |
Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
|
| O2 Concentration | 21 % |
| CO2 Concentration | 5 % |
| Medium | mTeSR™ 1 |
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| POU5F1 (OCT-4) |
Yes |
|
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
Normal 46, XY
Passage number: P14
Karyotyping method:
G-Banding
|
Other Genotyping (Cell Line) |
|
Genetic Modification
| Disease/phenotype related modifications |
|
Login to share your feedback, experiences or results with the research community.